Original language | English (US) |
---|---|
Pages (from-to) | 1100-1103 |
Number of pages | 4 |
Journal | Diabetologia |
Volume | 62 |
Issue number | 6 |
DOIs | |
State | Published - Jun 1 2019 |
Keywords
- Antiviral agents
- Clinical trials
- DiViD
- Enterovirus
- Islet
- nPOD
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Large enteroviral vaccination studies to prevent type 1 diabetes should be well founded and rely on scientific evidence. Reply to Skog O, Klingel K, Roivainen M et al [letter]. / Dunne, Jessica L.; Richardson, Sarah J.; Atkinson, Mark A.; Craig, Maria E.; Dahl-Jørgensen, Knut; Flodström-Tullberg, Malin; Hyöty, Heikki; Lloyd, Richard E.; Morgan, Noel G.; Pugliese, Alberto.
In: Diabetologia, Vol. 62, No. 6, 01.06.2019, p. 1100-1103.Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Large enteroviral vaccination studies to prevent type 1 diabetes should be well founded and rely on scientific evidence. Reply to Skog O, Klingel K, Roivainen M et al [letter]
AU - Dunne, Jessica L.
AU - Richardson, Sarah J.
AU - Atkinson, Mark A.
AU - Craig, Maria E.
AU - Dahl-Jørgensen, Knut
AU - Flodström-Tullberg, Malin
AU - Hyöty, Heikki
AU - Lloyd, Richard E.
AU - Morgan, Noel G.
AU - Pugliese, Alberto
N1 - Funding Information: Funding Work in the authors’ laboratories is supported by the South-Eastern Norway Regional Health Authority (grant to K.D.-J.), the Novo Nordisk Foundation (grants to KD-J and MF-T), the Swedish Child Diabetes Foundation (grant to MF-T), the Swedish Research Council (grant to MF-T), and by the PEVNET (Persistent Virus Infection in Diabetes Network) Study Group funded by the European Union’s Seventh Framework Programme (FP7/2007-2013) under grant agreement number 261441 PEVNET. Some of the authors (AP, SJR, NGM, HH, MAA, REL and MF-T) are supported by JDRF 3-SRA-2017-492-A-N, which funds the nPOD Virus Group in collaborative studies of virus infections in the pancreas with type 1 diabetes. Studies in the Exeter laboratory were supported by a JDRF-CDA award (5-CDA-2014-221-A-N to SJR), and by grant support from MRC (MR/P010695/1) and Diabetes UK (15/0005364) to SJR and NGM. MEC is supported by an Australian National Health and Medical Research Council (NHMRC) Practitioner fellowship [APP1045777] Duality of interest HH is a shareholder and member of the Board of Vactech Ltd., which develops picornavirus vaccines. HH and MF-T serve on the scientific advisory board of Provention Bio Inc., which is developing an enterovirus vaccine.
PY - 2019/6/1
Y1 - 2019/6/1
KW - Antiviral agents
KW - Clinical trials
KW - DiViD
KW - Enterovirus
KW - Islet
KW - nPOD
UR - http://www.scopus.com/inward/record.url?scp=85064810449&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85064810449&partnerID=8YFLogxK
U2 - 10.1007/s00125-019-4873-6
DO - 10.1007/s00125-019-4873-6
M3 - Letter
C2 - 31016358
AN - SCOPUS:85064810449
VL - 62
SP - 1100
EP - 1103
JO - Diabetologia
JF - Diabetologia
SN - 0012-186X
IS - 6
ER -